

The Open University's repository of research publications and other research outputs

Differential permissivity of human cerebrovascular endothelial cells to enterovirus infection and specificities of enterovirus 71 in crossing an in vitro model of human blood brain barrier

Journal Item

How to cite:

Volle, Romain; Archimbaud, Christine; Couraud, Pierre-Olivier; Romero, Ignacio A.; Weksler, Babette; Mirand, Audrey; Pereira, Bruno; Henquell, Cécile; Peigue-Lafeuille, Hélène and Bailly, Jean-Luc (2015). Differential permissivity of human cerebrovascular endothelial cells to enterovirus infection and specificities of enterovirus 71 in crossing an in vitro model of human blood brain barrier. *Journal of General Virology*, 96 pp. 1682–1695.

For guidance on citations see [FAQs](#).

© 2015 Society for General Microbiology

Version: Accepted Manuscript

Link(s) to article on publisher's website:
<http://dx.doi.org/doi:10.1099/vir.0.000103>

Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright owners. For more information on Open Research Online's data [policy](#) on reuse of materials please consult the policies page.

1 **Title**

2 Differential permissivity of human cerebrovascular endothelial cells to enterovirus infection
3 and specificities of enterovirus 71 in crossing an in vitro model of human blood brain barrier

4 **Authors**

5 Romain Volle^{1,2}, Christine Archimbaud^{1,2}, Pierre-Olivier Couraud⁴, Ignacio A. Romero⁵,
6 Babette Weksler⁶, Audrey Mirand^{1,2}, Bruno Pereira³, Cécile Henquell², Hélène Peigue-
7 Lafeuille^{1,2}, and Jean-Luc Bailly^{1,2*}

8 **Affiliations**

9 1 Clermont Université, Université d’Auvergne, EPIE, EA 4843, Clermont-Ferrand, France

10 2 CHU Clermont-Ferrand, Service de Virologie, Clermont-Ferrand, France

11 ³ CHU Clermont-Ferrand, DRCI, Clermont-Ferrand, France

12 ⁴ Inserm, U1016, Institut Cochin, Paris, France

13 ⁵ Department of Life, Health and Chemical Sciences, Open University, Milton Keynes, U.K

14 ⁶ Weill Cornell Medical College, New York, NY, USA

15 **Running title**

16 Impairment of the blood brain barrier by enteroviruses

17 **Word counts:** Abstract, 203; Main text, 5429

18 **Correspondent footnote:** Jean-Luc Bailly

19 Phone: +33 4 73 17 81 42; Fax: +33 4 73 75 48 51; j-luc.bailly@udamail.fr

20

21 **ABSTRACT**

22 Human cerebral microvascular endothelial cells (hCMEC/D3 cell line) form a steady polarized
23 barrier when cultured *in vitro* on a permeable membrane. Their susceptibility to enterovirus
24 (EV) strains was analysed to investigate how these viruses may cross the blood-brain barrier.
25 A sample of 88 virus strains was selected on phylogenetic features among 44 epidemiologically
26 relevant types of the four EV species A–D. The EV-A71 genome was replicated at substantial
27 rates while the infectious virus was released at extremely low but sustained rates at both barrier
28 sides for at least 4 days. EV-A71 antigens were detected in a limited number of cells. The
29 properties of the endothelial barrier (structure and permeability) remained intact throughout
30 infection. The chronic EV-A71 infection was in sharp contrast with the productive infection of
31 cytolytic EVs (**e.g.** echoviruses 6 and 30). The hCMEC/D3 barriers infected with the latter EVs
32 exhibited elevated proportions of apoptotic and necrotic cells, which resulted in major injuries
33 to the endothelial barriers with dramatic increase of paracellular permeability and virus
34 crossing to the abluminal side. The following intracellular rearrangements were also seen: early
35 destruction of the actin cytoskeleton, remodelling of intracellular membranes, and
36 reorganization of the mitochondrion network in a small cluster near the perinuclear space.

37

38 INTRODUCTION

39 Enteroviruses (EVs; *Picornaviridae*) form a large group of non-enveloped enteric viruses, of
40 which more than 100 different serotypes are human pathogens classified within four taxonomic
41 species (EV-A to EV-D). Human EVs are transmitted through faecal-oral and respiratory
42 routes and they actively replicate in the mucosa and epithelial cells of the throat and intestinal
43 tract. Viral invasion of the intravascular space or viremia may result in spreading to sites such
44 as the skin, heart and central nervous system (CNS).

45 The most common clinical manifestation associated with CNS EV infections is aseptic
46 meningitis. Encephalitis, cerebellitis, myelitis, and poliomyelitis are also observed but less
47 frequently (Khetsuriani *et al.*, 2006; Antona *et al.*, 2007). There is evidence for hematogenous
48 and neural routes of poliovirus (PV) dissemination and both involve viremia (Sabin, 1956); the
49 two routes are not mutually exclusive. By the neural pathway, it is suggested that the virus is
50 conveyed by retrograde axonal transport from infected tissues to the CNS via peripheral nerves
51 (Ren & Racaniello, 1992; Gromeier & Wimmer, 1998). In mouse models, PV can be
52 transported along nerves through either a process involving the CD155 receptor or a receptor-
53 independent manner (Okha *et al.*, 2012). Investigations with different animal models have
54 revealed a possible link between neurological injury caused by enterovirus A71 (EV-A71) and
55 retrograde axonal transport of the virus to the CNS (Chen *et al.*, 2007; Khong *et al.*, 2012). The
56 occurrence of encephalomyelitis and subsequent paralysis associated with these two EVs could
57 be explained by transport via the neural pathway but the inefficiency of the axonal transport
58 limits virus access to the CNS (Lancaster & Pfeiffer, 2010).

59 Alternatively, a virus in the bloodstream may enter the CNS by crossing the vascular
60 endothelium in the meninges, the choroid plexus, or the brain parenchyma. PV-1 was suggested
61 to cross the mouse blood-brain barrier (BBB) independently of the CD155 receptor and of
62 infected leucocytes (Yang *et al.*, 1997). During EV-A71 infection, viremia early after the onset

63 of disease was related to severe CNS involvement in young children (Cheng *et al.*, 2014) and
64 to neurological impairment in experimentally infected rhesus monkeys (Zhang *et al.*, 2011). In
65 neonates infected with coxsackievirus B3 (CV-B3), a high blood viral load was related to
66 greater disease severity (Yen *et al.*, 2007). Using sensitive quantitative gene amplification
67 techniques to amplify viral RNA from the cerebrospinal fluid (CSF), it is possible to detect
68 evidence of EV infection of the CNS in patients with aseptic meningitis early after the onset of
69 disease in both children and adults (Volle *et al.*, 2014). Our current knowledge about the
70 processes involved in EV immigration into the CSF is still limited. As this inflammatory
71 disease of the subarachnoid space is common to most EV serotypes, it is assumed that viruses
72 travel through the blood, breaching the blood-CSF barrier either directly or through infected
73 leukocytes. A number of studies showed that PV, CV-B3, and EV-A71 can infect various
74 immune cells (Eberle *et al.*, 1995; Vuorinen *et al.*, 1996; Haddad *et al.*, 2004; Wahid *et al.*,
75 2005a; 2005b; Tabor-Godwin *et al.*, 2010). These data suggest a role of infected leukocytes in
76 EV dissemination to the CNS through a “Trojan-horse” process. In vitro studies showed the
77 susceptibility to different EVs of human vascular endothelial cells of different tissue
78 origins (Conaldi *et al.*, 1997; Ylipaasto *et al.*, 2010; Saijets *et al.*, 2003; Liang *et al.*, 2004;
79 Zanone *et al.*, 2003; Bozym *et al.*, 2010). In addition, PV-1 and CV-B3 induce different cell
80 signalling and endocytosis pathways in human brain microvascular endothelial cells
81 (HBMEC), which is suggestive of possible variations in BBB crossing between EV types
82 (Bozym *et al.*, 2010; Coyne *et al.*, 2007).

83 In this study we used the human cerebral microvessel endothelial cell line D3
84 (hCMEC/D3) as a model of brain endothelium (Weksler *et al.*, 2005; 2013). The hCMEC/D3
85 cells were used as a model for investigating whether or not EVs can breach an endothelial
86 barrier. We first examined the susceptibility of hCMEC/D3 cells to infection by a set of 44 EV
87 serotypes and then analysed the ability of a subset of EVs to cross endothelial barriers.

88

89 RESULTS

90 **Susceptibility of hCMEC/D3 cells to 44 EV types.** We used a first set of 88 virus strains
91 (**Table S1**) chosen within species B (EV-B; n=37 types), EV-A (n=5), EV-C (n=1), and EV-D
92 (n=1). Susceptibility of hCMEC/D3 cells to EV strains was assessed in duplicate at 24 h p.i.
93 by measurement of the production of viral RNA and infectious virus (**Fig. S1**). The virus yield
94 exhibited a positive correlation (Spearman's rho 77%, p-value <0.001) with viral RNA
95 production (**Fig. 1a**). The virus strains selected among the EV-B types displayed different
96 replication patterns defined by two arbitrarily selected thresholds of 0.00 log₁₀ infectious
97 particles and 3.00 log₁₀ genome copies per cell. The highest infectivity rates (from -0.55 to
98 2.86 log₁₀ infectious particles per cell and 2.12 to 5.53 log₁₀ genome copies per cell) were
99 determined for the epidemiologically infrequent types echovirus 1 (E-1) and EV-B69 and the
100 epidemic types E-6, E-11, E-12, E-13, and E-30. The strains selected among CV-B and EV-A
101 types displayed the lowest infectivity rates (respectively, from -2.89 to 0.01 and -2.38 to -0.41
102 log₁₀ infectious particles per cell, and -0.44 to 3.53 and 2.01 to 4.51 log₁₀ genome copies per
103 cell).

104 Kinetics of viral RNA production performed in triplicate for EV-A71, E-6, E-30, and
105 E-12 strains showed the highest rates of virus replication between 2 and 6 h p.i. (p-value 0.001;
106 **Fig. 1b**). Different peaks of viral RNA production were reached at 24 h p.i. among the viruses
107 tested (mean±SD in log₁₀ copies per cell): EV-A71 (3.29±0.58), E-30 (4.15±0.30), E-6
108 (5.30±0.25), and E-12 (5.56±0.21). These RNA levels were consistent with those obtained in
109 **Fig. 1a**: 2.46±0.63, 3.85±0.26, 5.02±0.15, and 5.46±0.15, respectively.

110 We determined the number of infected cells at 6 h p.i. (before extensive release of virus
111 progeny) to investigate whether the variations in susceptibility of hCMEC/D3 cells were
112 related to differences in the infection efficiencies of EV strains. The infected cells were
113 numbered in triplicate by computer-assisted image processing of low magnification

114 epifluorescence pictures. The highest proportion of infected cells (>30%) was determined for
115 E-19, EV-B69, and E-1, and intermediate proportions of 10–30% were obtained with E-12 and
116 E-16 (**Fig. 1c**). Less than 10% of infected cells were counted for virus strains of various types
117 (E-30, E-3, E-7, CV-B6, E-4, E-14, E-18, EV-A71, E-9, E-32, CV-B3, and E-25). About 20
118 infected cells per cm² were counted for E-27 and E-11, and only 3–5 infected cells per cm² for
119 EV-B70, EV-B77, CV-A9, E-15, E-24, and E-26 (data not shown). Two E-6 and E-13 strains
120 exhibited different infection efficiencies (E-6/CF2660-01 >30%; E-6/CF158061-11 and E-
121 13/CF1275-00 10–30%; E-13/CF1925-01 <10%). The overall data suggest variations in the
122 susceptibility of the hCMEC/D3 cells to infection by different EV types and subtypes.

123

124 **Cell mortality during virus infection and multidimensional analysis of EV infectivity.** The
125 mortality rates of infected hCMEC/D3 cells were determined in quadruplicate at 24 h p.i. for a
126 subset of 15 EV strains representative of different susceptibility patterns determined above in
127 hCMEC/D3 cells (**Fig. 1d**). The mortality threshold was defined by the highest value of the
128 standard deviation calculated with mock infected cells (i.e. 10%). High cell mortality rates
129 >50% were found with E-1 and EV-B69, and cell death resulted from both necrosis and
130 apoptosis. Intermediate cell mortality rates between 40 to 50% were estimated for E-12, E-
131 6/CF2660-01, and E-30/CF282-97. Other virus strains of the two latter types caused lower cell
132 mortality (30–40%). Two E-13 strains were related to different cell mortality rates (CF1274-
133 00, 38.3%; CF1925-01, <30%). Mortality of cells infected with EV-A71 (11%) was similar to
134 that of mock infected cells.

135 We used principal component analysis (PCA) to visualize on a map the ordination of
136 the 15 EV strains according to the proportion of infected cells, the production of viral genomes,
137 the yield of infectious particle production, and cell mortality rates (**Fig. S2**). The proportion of
138 infected cells and cell mortality exhibited a positive correlation, hereafter designated cell

139 sensitivity (x-axis). The productions of viral genomes and infectious virus were positively
140 correlated and designated as viral replication (y-axis). As cell sensitivity and viral replication
141 were orthogonal, they were not correlated with each other. PCA confirmed that the hCMEC/D3
142 cell line displayed large differences in sensitivity to EV types and strains within the same type
143 (**Fig. 2**). We selected viral strains representative of different PCA patterns for further
144 investigations with endothelial barriers (Table S2).

145

146 **Variations in permeability and structural integrity of endothelial barriers among EV**
147 **types.** We prepared endothelial barriers *in vitro* with the hCMEC/D3 cells (see **Fig. S3**) and
148 quantified infection with five EV types so that infection and paracellular permeability were
149 assessed in the same samples. The structural features of mock-infected endothelial monolayers
150 and their restrictive permeability were analysed with transmission electron microscopy (TEM)
151 and clearance of a non-permeable fluorescent compound (**Figs. S3 and S4**). Endothelial
152 barriers infected with E-6, E-11, E-12, and E-30 strains exhibited little change in paracellular
153 permeability at 24 h p.i. but permeability progressively increased afterwards (**Fig. 3a–3d**). A
154 release of viral genomes ($>6 \log_{10}$ copies) was detected at 6 h p.i. at both barrier sides, but in
155 the abluminal compartment, viruses were detectable below the titration threshold for E-12 and
156 E-30. The release of infectious progeny reached highest levels at 24–48 h p.i. Scanning electron
157 microscopy (SEM) allowed the identification of three main cytological alterations (**Fig. 4**).
158 Compared to mock infected controls, which had the appearance of joined cobblestones (**Fig.**
159 **4a–4c**), the infected endothelial barriers exhibited cells with structural features suggestive of
160 necrosis (damage plasma membrane) and apoptosis (preserved and budded plasma membrane),
161 indicated, respectively, by red and green arrow heads in **Fig. 4d–4l**. Rounded cells without
162 apparent altered plasma membrane were suggestive of early steps of cell death (see blue arrow
163 heads). On the basis of these analyses, we found evidence of large amounts of altered cells,

164 which caused breaches within endothelial barriers, as indicated by the visualization of pores of
165 the microporous membrane (white arrow heads).

166 The paracellular permeability of endothelial barriers infected with the EV-A71 strains
167 (genogroups C1 and C2) was maintained at levels similar to those of mock-infected barriers
168 until 96 h p.i. (**Fig. 3e and 3f**). The abluminal release of EV-A71 genomes and infectious virus
169 was highest at 24 h p.i. and remained constant at slightly lower levels up to 96 h p.i. The
170 infectious progeny was below the titration threshold at the abluminal side after 24 h p.i., but
171 was consistently determined at low levels at the luminal side. SEM observations showed few
172 groups of infected cells and a limited number of small breaches (**Fig. 4m–4o**).

173

174 **Intracellular changes in endothelial barriers during EV infection.** The endothelial barriers
175 were analysed by TEM to visualize the intracellular features of infected hCMEC/D3 cells and
176 to investigate variations between EV types. The altered cells of endothelial barriers infected
177 with the E-6/CF2660-01 strain displayed features indicative of virus infection, which were
178 similar to those caused by E-30 and E-12 (data not shown). At 24 h p.i., the impaired cells
179 displayed shrunken nuclei relocated near the cell membrane and contained myriads of virus-
180 induced vesicle-like membranous structures, 200 nm in diameter (**Fig. 5a and 5b**). These
181 structures had either single or double membranes and were organized in extensive intracellular
182 arrangements (**Fig. 5c**). Some infected cells showed evidence of tubular structures with
183 positive membrane invagination that enclosed cytoplasmic components (**Fig. 5d**). Clusters of
184 electron-dense granules between membranous structures were suggestive of viral particles
185 (**Fig. 5e**). Mitochondria were grouped near the membranous structures, which contrasted with
186 mock-infected cells, in which mitochondria formed an extensive network (**Fig. S4**). Large
187 single-membrane vesicles (600–1000 nm in diameter) contained electron-dense cytoplasmic
188 material and multilamellar structures resembling autophagic vacuoles (**Fig. 5c**).

189 In contrast to the features described above, the impaired cells of endothelial barriers
190 infected with EV-A71/CF166105-10 displayed a number of structural variations. As shown in
191 **Fig. 6a–6d**, the EV-A71 infected cells maintained an elongated shape and contained nuclei
192 similar in shape to those seen in control barriers. Remodelling of intracellular components
193 included vesicle-like structures and mitochondria clustered near the nucleus whereas EV-A71-
194 induced membranous structures had a uniform round shape with a diameter of 500 nm and a
195 multilamellar structure (**Fig. 6e–6i**).

196

197 **Intracellular injury patterns common to EV types.** The early virus-induced intracellular
198 injuries at 6 h p.i. were further analysed by confocal microscopy and viral replication was
199 detected by staining the VP1 protein. The infected cells displayed major reduction in staining
200 of polymerized actin in comparison to controls (**Fig. 7a–7r vs Fig. 7s–7u**). This indicates
201 effective cytoskeleton impairment early after the initiation of viral protein synthesis and would
202 explain the subsequent cell rounding.

203 Early virus-induced changes in the mitochondrion network were analysed with a
204 fluorescent probe that accumulates in active mitochondria. Mitochondria were stained in all
205 virus-infected cells (**Fig. 8a–8o**) but, in contrast to mock-infected controls, they were clustered
206 in a perinuclear area (**Fig. 8p–8r**). Rearrangement of the mitochondrion network was marked
207 in cells exhibiting prominent staining of the VP1 protein at 6 h p.i. (see white arrowheads).
208 Cells with reduced VP1 staining exhibited no or minor changes in the mitochondrion network
209 (see yellow arrowheads). Mitochondrion clustering was dependent on viral replication
210 intensity but was not directly related to cell rounding, since cells that were not yet round were
211 also displaying clustered mitochondria.

212

213 **DISCUSSION**

214 Human EV infections are associated with meningitis, encephalitis, and encephalomyelitis but
215 our current knowledge about CNS invasion by enteric viruses is still scant. The BBB may
216 represent a common entry pathway for EVs during viremia, which precedes disease onset. In
217 this study, we used the human cerebral microvascular endothelial cell line hCMEC/D3 as a
218 model system for investigating EV entry routes into the CNS through the human BBB. We
219 showed that the hCMEC/D3 cells were permissive to infection by a large array of EVs and
220 found major differences between types and genogroups. Most EV strains occupied a central
221 position in the susceptibility spectrum of hCMEC/D3 cells, notably the E-6, E-13, and E-30
222 strains, and intratypic variations may be related to individual genetic differences among
223 genogroups and subgenogroups. A wide range of cellular receptors has been observed in
224 human EVs (reviewed in Merilahti *et al.*, 2012). Although we did not examine the binding
225 processes of EVs to the hCMEC/D3 cell surface, there is a large body of earlier experimental
226 evidence to suggest that the intertypic variations in hCMEC/D3 susceptibility to EVs can be
227 attributed to their propensity for using a wide range of receptors and internalization processes
228 (Ylipaasto *et al.*, 2010; Coyne *et al.*, 2007; Bozym *et al.*, 2010). For instance, E-1 stands apart
229 within the susceptibility spectrum of hCMEC/D3 cells to EV infection, a pattern which may
230 be related to the fact that it is the only type known to bind integrin $\alpha 2\beta 1$ (Bergelson *et al.*,
231 1993). A number of EV types examined in our study (E-6, E-11, E-12, E-13, and E-30) bind
232 the same cellular receptor CD55 (Bergelson *et al.*, 1995). Yet, the virus strains of these types
233 did not cluster in the same area of the susceptibility spectrum of hCMEC/D3 cells. This
234 suggests that additional factors other than canonical receptors should be considered and that
235 genogroup features may be involved.

236 Our investigation provides evidence of two major clusters among EV types. A first
237 cluster consists of the EVs that exhibit a highly cytolytic phenotype, produce infectious

238 progeny, and induce extensive disruption of the endothelial barrier. Early during cellular
239 infection by these viruses, the amount of virus genomes released in the abluminal compartment
240 was >10,000 times higher than that of infectious progeny. We assumed that paracellular
241 transport of viral RNA and defective virus particles was not involved because barrier
242 permeability to the fluorescent reporter was not yet compromised at this time, a hypothesis that
243 is also supported by SEM observations. At 24 h p.i., the difference between the release of viral
244 genomes and virus particles was substantially reduced at the abluminal side as a result of the
245 destruction of the endothelial barrier caused by infected dying cells. In contrast, the release of
246 genomic material was relatively constant over time at the luminal sides. Accordingly, massive
247 amounts of viral genomes appeared to drain off the cells through their basolateral membrane
248 early during infection by a yet unknown process.

249 The second cluster comprises CV-B and EV-A71 types, which produced no impairment
250 of the *in vitro* model of endothelium barrier. A key observation, in sharp contrast with the
251 above data, is that hCMEC/D3 cells are moderately permissive to EV-A71 infection. This
252 pattern resulted from a high replication rate of the viral genome but a remarkably poor
253 production of infectious viruses. Both the virus and viral RNA were released from the luminal
254 and basolateral sides of the endothelial barrier but at disproportionately different rates as the
255 infectious virus was consistently detected at minute amounts. This process was maintained for
256 at least 4 days and did not induce a breakdown of the barrier nor changed the paracellular
257 permeability as measured with the LY surrogate marker. This non-disruptive pattern occurred
258 even when the barriers were inoculated with a MOI of about 100 TCID₅₀ per cell (data not
259 shown), which suggests that it was not dependent on the initial infection conditions but was
260 more probably related to post-entry factors. A non-disruptive and long-term replication pattern
261 was also shown for CV-B3 and CV-B5 (data not shown). A persistent replication was reported
262 earlier for CV-B3 and CV-B4 in human dermal microvascular endothelial cells (Zanone *et al.*,

263 2003). A flavivirus West Nile virus can cross *in vitro* BBB models by infection of endothelial
264 cells (Verma *et al.*, 2009). The brain endothelium crossing and infection by West Nile virus is
265 not related to direct disturbance of the endothelial barrier integrity *in vitro*, as observed in our
266 study for EV-A71 and CV-B. The loss of BBB integrity associated with the West Nile virus
267 may be related to up regulation of cell adhesion molecules (e.g. VCAM-I, E-Selectin) in
268 infected endothelial cells, thus promoting trans endothelial migration of leucocytes *in vivo*
269 (Verma *et al.*, 2009; 2010).

270 The infected cells showed typical ultrastructural features of a picornavirus infection.
271 We found evidence for both apoptosis and necrosis among infected cells regardless of the EV
272 type, in agreement with data indicating a competition between cell death pathways and
273 picornavirus replication (Agol & Gmyl, 2010). We also observed disruption of the actin
274 cytoskeleton network and that of intercellular junctions as evidenced by the rounding of
275 infected cells. The actin cytoskeleton has an important role in the maintenance of stable inter
276 endothelial junctions and prevents paracellular transport to the brain (Stamatovic *et al.*, 2012;
277 Spindler & Hsu, 2012). Remodelling of intracellular membranes was the third hallmark of a
278 picornavirus infection seen in infected hCMEC/D3 cells but discrete variations occurred
279 between echoviruses (E-6, E-12, and E-30) and EV-A71. In the echovirus infections, we found
280 evidence of single and double membrane vesicles organized in compact arrangements near the
281 nucleus and of structures that displayed positive membrane invagination. Both features were
282 reported earlier in Vero and Hela cells infected by CV-B3 and PV-1, respectively (Limpens *et*
283 *al.*, 2011; Belov *et al.*, 2012). The vesicular structure in the EV-A71 infected hCMEC/D3 cells
284 was characterised by less condensed vesicles and an increased proportion of multilamellar and
285 large vesicles. Finally, our analyses with TEM and fluorescence microscopy showed clustering
286 of the mitochondrion network, a previously unobserved feature of EV infections that occurred
287 early during the virus infection and whose origin is still unclear. It may be related to virus-

288 induced disruption of microtubules, as suggested for cells infected with the hepatitis B virus
289 (Kim *et al.*, 2007). A similar feature was also reported for African swine fever virus, another
290 DNA virus, and was related to coupling between viral translation and ATP synthesis (Rojo *et*
291 *al.*, 1998).

292 The most frequent EV infections of the CNS cause meningitis as a result of virus
293 replication in the cells of the leptomeninges, the brain coverings (Rotbart, 1995). These
294 infections are usually self-limited because the meninges are directly accessible to immunologic
295 surveillance and subject to rapid immune responses (Engelhardt & Coisne, 2011). The varying
296 amounts of viruses in the CSF of patients with EV meningitis within few hours after the onset
297 of symptoms (Volle *et al.*, 2014) may reflect virus unloading from these infected sites. The
298 meningeal blood vessels, which form the barrier between blood and CSF, are only made of
299 non-fenestrated endothelial cells; this contrasts with the BBB, which includes other cell types.
300 Accordingly, our endothelium model is consistent with the blood-CSF barrier. The infection
301 of endothelial cells reported in this study for a large array of EV types may occur during the
302 earliest stages of viremia, which develops following EV replication in peripheral tissues. The
303 local EV replication may contribute to infection of leptomeninges and development of a neuro-
304 inflammatory disease. Of note, regional blood flow reduction and cerebral vasculitis can be
305 observed in children with E-30 aseptic meningitis (Nishikawa *et al.*, 2000). Care must be taken
306 in making generalised conclusions of pathophysiology based on *in vitro* model systems and
307 the transcellular passage for neural spread of EVs requires close examination in an appropriate
308 *in vivo* model.

309

310 MATERIALS AND METHODS

311 **Cell lines and viruses.** HCMECs were grown in EBM-2 basal medium (Lonza) supplemented
312 with 5% fetal bovine serum (FBS), 1% penicillin (10,000U), 1% streptomycin (10mg/ml; GE
313 Healthcare Life Science), 1% chemically defined lipid concentrate (Invitrogen), 10 mM of
314 HEPES, 1.4 μM of hydrocortisone (Sigma Aldrich), 1.5 $\mu\text{g}\times\text{ml}^{-1}$ of ascorbic acid (Sigma
315 Aldrich), and 200 $\text{ng}\times\text{ml}^{-1}$ of basal fibroblast growth factor (Sigma Aldrich). The cells were
316 seeded for all experiments on rat collagen I-coated culture surfaces (RD-System). The
317 rhabdomyosarcoma (RD) cells were grown in RPMI 1640 medium (Lonza) with 1%
318 penicillin/streptomycin, and 4% FBS. The buccal epithelial carcinoma (KB) cells were grown
319 in DMEM basal medium (GE Healthcare Life Science) with 1% penicillin/streptomycin, and
320 6% FBS. All cell cultures were maintained at 37°C in a humidified atmosphere containing 5%
321 CO_2 .

322 A sample of 88 EV strains, comprising 23 reference strains and 65 clinical isolates,
323 recovered from patient specimens (CSF, stool or throat) was used in the study (**Table S1**).
324 Virus stocks were prepared with KB (coxsackievirus B) and RD cells (other EVs) and stored
325 at -20°C . Titration of viral suspensions was done using our end point dilution assay (Bailly *et*
326 *al.*, 1991). The cell cultures were inoculated at a multiplicity of infection (MOI) of 5 for 1 h at
327 37°C in all experiments; after washing with PBS, they were incubated for the indicated times.

328 **Extraction of nucleic acids and EV real-time RT-qPCR.** Nucleic acids were extracted from
329 200 μl from supernatants or the whole cells and supernatant using the NucliSens[®]EasyMAG[™]
330 extractor (bioMérieux) and were eluted with 25 μl of the elution buffer provided by the
331 manufacturer. A previously described competitive internal control was added during the
332 extraction step and amplified in our in-house RT-qPCR assay (Volle *et al.*, 2012).

333 **Viability of infected hCMEC/D3 cells.** Cells were infected separately by 15 EV strains. After
334 two washes at 24 h p.i., the cells were detached, centrifuged for 10 min at 1000g, stained with

335 the Apoptotic/Necrotic/Healthy Cells Detection Kit (Promokine), and analysed by flow
336 cytometry (BD-LSRII, BD Bioscience). Cells were considered as being viable when only
337 stained with the Hoechst compound, apoptotic when only stained with the Annexin V
338 conjugated antibody, or necrotic when they were stained with both Annexin V and ethidium
339 homodimere III. Cell fragments were detected through ethidium homodimere III staining
340 alone.

341 **Fluorescent microscopy.** HCMEC/D3 cells were grown in chamber slides, infected for 6
342 hours by different EV strains, and fixed with 4% paraformaldehyde for 10 min. For
343 mitochondria staining, the cells were incubated at 37°C for 1 h before fixation, with complete
344 EBM-2 medium containing 50 nM of MitoTracker® Mitochondrion-Selective probe M7510
345 (Invitrogen) in a humidified atmosphere of 5% CO₂. Cells were permeabilized with 0.5%
346 Triton X100 in PBS for 5 min, saturated for 10 min with 5% BSA in PBS, and incubated
347 overnight at 4°C with mouse primary monoclonal antibodies against the EV capsid protein
348 VP1 (Diagnostic Hybrid). After three PBS washes, incubation was pursued for 1 h at 37°C in
349 a solution of anti-mouse secondary antibodies conjugated to Dyelight488 (Anticorps enligne).
350 In the tests for which active mitochondria staining was not required, red-phalloïdin used for
351 actin staining was included in the secondary antibody solution. After three PBS washes, nuclear
352 DNA was counterstained with a Hoechst solution (Promokine). The slides were mounted with
353 coverslips and observed with an epifluorescence microscope (Olympus BX41) or scanning
354 confocal microscope (LSM 510, Carl Zeiss MicroImaging Inc.). Automated image analysis
355 (FIJI software) was used to calculate the number of infected cells.

356 **EV crossing through an *in vitro* model of brain microvascular endothelial barrier.** To
357 obtain microvascular endothelial barriers, hCMEC/D3 cells were cultured on a permeable
358 membrane (0.4 µm pore) placed in the upper chamber of a Transwell® device (12-well plate,
359 Corning). The upper chamber was seeded with 40,000 cells/cm² and incubated for 5 to 7 days

360 to obtain a tight confluent cell monolayer. In this *in vitro* model, the cells are polarized and
361 display a luminal side and an abluminal side (Weksler *et al.*, 2005). The luminal sides of non-
362 permeable barriers were exposed separately to various EV strains, the infected barriers were
363 incubated for the indicated times, and permeability was determined at each time p.i. (see
364 below). The yield of infectious particles and the total amount of viral genome released through
365 the abluminal and luminal sides were determined as described above.

366 **Lucifer Yellow permeability assay.** The paracellular seal of the endothelial barrier was
367 determined in triplicate by testing the permeability to the Lucifer Yellow marker (LY, Sigma).
368 The cell monolayers were washed twice with collecting buffer consisting of HBSS (GE
369 Healthcare Life Science) supplemented with 1% of HEPES (GE Healthcare Life Science) and
370 1% of sodium pyruvate (GE Healthcare Life Science). The LY marker (50 μ M; 400 μ l) was
371 added to the upper chamber. Cells were incubated at 37°C (5% CO₂ and 100% humidity) in
372 three successive collecting wells, each containing 1.6 ml of collecting buffer, for respectively
373 10, 15, and 20 min. The LY concentration in the collecting buffer of each well and the stock
374 LY solution were determined by fluorometry. Parallel negative control tests were performed
375 with cell-free collagen-coated culture membranes. Samples were analysed in black 96-well
376 microtiter plates using a Fluoroskan Ascent FL fluorometer (Thermo Electron Corporation,
377 France) at 485 and 538 nm wavelengths for excitation and emission, respectively.

378 **Scanning and transmission electron microscopy (SEM and TEM).** The endothelial barriers
379 were washed with 0.2M Na cacodylate buffer (NCB; pH 7.4) and fixed overnight at 4°C in
380 1.6% glutaraldehyde-NCB. The cells were fixed for 1 h with 1% OsO₄ in NCB. For SEM
381 preparation, cells were dehydrated in graded ethanol, followed by critical point drying with
382 100% ethanol and hexamethyldisilane (1:1) for 10 min, sputter-coated with gold (JEOL JFC-
383 1300), and observed at 5kV with a JEOL 6060-LV microscope. For TEM preparation, cells
384 were dehydrated in graded ethanol, infiltrated sequentially with three mixtures of

385 ethanol/EPON resin (2:1, 1:1, and 1:2) for 1 h each, embedded in EPON resin overnight at
386 room temperature, and cured 2 days in a 60°C oven. Thin sections (70 nm, UC6
387 ultramicrotome, Leica) were stained with uranyl acetate and Pb citrate, and observed at 80 kV
388 with a Hitachi H-7650 microscope. All chemical products were provided by Delta
389 Microscopies.

390 **Statistical Analysis.** Statistical analyses were made with software Stata (version 12,
391 StataCorp, College Station, US). Tests were two-sided, with a type I error set at $\alpha=0.05$.
392 Quantitative data are expressed as means (and associated standard deviation, Gaussian
393 distribution verified by the Shapiro-Wilk test). Correlated data were analysed by mixed models
394 to study the evolution of parameters taking into account between and within strain variability
395 (random effects such as intercept and slope). These analyses were completed by ANOVA for
396 repeated measures followed by post-hoc Tukey-Kramer test. Principal component analysis was
397 done to explore the relation between several quantitative parameters. Correlation coefficients
398 (Pearson or Spearman when appropriate) were calculated to quantify these relations.

399

400 **LEGENDS TO FIGURES**

401 **Fig. 1. Heterogeneity of enterovirus infection in hCMEC/D3 cells.** Replication in
402 hCMEC/D3 cells of EV strains selected among species, types, and genogroups was examined
403 at 24 h p.i. (a) Data are represented as means of two independent assays and given as the
404 number of viral genome copies per cell (x-axis) and of infectious particles per cell (y-axis).
405 Correlation between the yield of virus genome and yield of infectious virus is indicated. (b)
406 Replication kinetics of virus strains of four EV types in hCMEC/D3 cells. Data are
407 representative of means of three independent replicates for each virus E-30 (●), E-6 (▲), E-12
408 (◆), and EV-A71 (×). (c) Susceptibility spectrum of the hCMEC/D3 cell line to EVs estimated
409 as the proportion of infected cells at 6 h p.i. A sample of 24 viral strains representing 19
410 different types was tested. Green and blue fluorescence indicate the VP1 protein and the nuclei,
411 respectively. Scale bar, 100 μm. Data are represented as mean ± SD of three experiments. (d)
412 Comparison of cell mortality rates at 24 h p.i. (n=15 EV strains). Data are represented as mean
413 ± SD of four independent experiments. The blue line indicates the cell mortality rate (10%) in
414 mock-infected cells (NoV).

415

416 **Fig. 2. Principal component analysis of enterovirus replication in hCMEC/D3 cells.**
417 Ordination of the data obtained for 15 EV strains using principal component analysis. The
418 horizontal axis is linked to cell sensitivity to EVs and the vertical axis to virus production.

419

420 **Fig. 3. Disruption of a microvascular endothelial barrier during enterovirus infection.**
421 Endothelial barriers of hCMEC/D3 cells produced on Transwell® membranes were infected
422 with E-6/CF2660-01 (a), E-11/CF228046-07 (b), E-12/CF1157-91 (c), E-30/CF2575-00 (d),
423 EV-71/CF166105-10 (e), and EV-A71/CF160019-10 (f). At the indicated time points, the
424 culture mediums in the luminal and abluminal compartments were collected and stored

425 separately. Paracellular permeability was measured. Data are indicated as mean \pm SD of three
426 experiments. The number of EV genome copies and infectious virus particles are respectively
427 indicated with white and light grey bars for the luminal compartment, and respectively with
428 dark grey and dashed bars for the abluminal compartment. Permeability coefficients for mock
429 infected and infected barriers are indicated with green and red lines, respectively.

430

431 **Fig. 4. Disruption of endothelial barriers during enterovirus infection.** The hCMEC/D3
432 barriers were analysed with SEM at 24 h p.i. Representative fields of duplicate experiments
433 are shown: mock-infected monolayers (a–c), and barriers infected with E-6/CF2660-01 (d–f),
434 E-12/CF1157-91 (g–i), E-30/CF2575-00 (j–l), and EV-A71/CF166105-10 (m–o). White arrow
435 head, breach of the endothelial barriers; red and green arrow heads, cells with a necrotic and
436 an apoptotic shape, respectively; blue arrow head, round cell with no sign of altered plasma
437 membrane.

438

439 **Fig. 5. Ultrastructural features at 24 h p.i. of hCMEC/D3 barriers infected with an E-6**
440 **strain.** The infected hCMEC/D3 barriers were observed at low magnification with TEM (a and
441 b). Virus-induced reorganization of cytoplasmic elements (c). Features of the vesicular
442 structures (d). Dense electron punctuation suggestive of virus aggregates (e). Bars, 4 μ m (a and
443 b); 500 nm (c–e). Representative fields of duplicate experiments are shown; mock-infected
444 cells are shown in figure S4. Abbreviations: N, nucleus; M, mitochondria; MC, membranous
445 replication complex; A, autolysosome/amphisome; V, virus aggregates.

446

447 **Fig. 6. Ultrastructural features at 24 h p.i. of hCMEC/D3 barriers infected with an EV-**
448 **A71 strain.** The infected hCMEC/D3 barriers were analysed at low magnification with TEM;
449 unaltered cells (a and b) and altered cells with virus-induced vesicular structures (c and d).

450 Features of the vesicular structures (e–i). Bar, 10 μm (a–d); 1 μm (e and f); 500 nm (g–i).
451 Representative fields of duplicate experiments are shown; mock-infected cells are shown in
452 figure S4. Abbreviations: N, nucleus; M, mitochondria; MC, membranous replication complex.
453

454 **Fig. 7. The actin cytoskeleton network is disrupted in enterovirus-infected hCMEC/D3**
455 **cells.** The hCMEC/D3 cells were analysed at 6 h p.i. during replication of strains E-12/CF1157-
456 91 (a–c), E-6/CF2660-01 (d–i), E-30/CF2575-00 (j–l), E-11/CF228046-07 (m–o), and EV-
457 A71/CF166105-10 (p–r); mock-infected cells (s–u). Actin network is shown in red, VP1 capsid
458 protein in green, and nuclei in blue. Bars represent 10 μm . White arrow heads indicate
459 intermediate disruption of actin cytoskeleton.

460

461 **Fig. 8. Perinuclear relocation of active mitochondria in enterovirus-infected hCMEC/D3**
462 **cells.** The hCMEC/D3 cells were analysed at 6 h p.i. during replication of E-12/CF1157-91
463 (a–c), E-6/CF2660-01 (d–f), E-30/CF2575-00 (g–i), E-11/CF228046-07 (j–l), and EV-
464 A71/CF166105-10 (m–o); mock-infected cells (s–u). Active mitochondria are shown in red,
465 VP1 capsid protein in green, and nuclei in blue. Bars represent 10 μm . White and yellow arrow
466 heads indicate dense clusters and intermediate clustering of mitochondria, respectively.

467

468 **ACKNOWLEDGEMENTS**

469 The authors acknowledge the technical contribution of Gwendoline Jugie, Nathalie Rodde, and
470 Isabelle Simon for helpful assistance in virus culture and sequencing. We thank Mr. Jeffrey
471 Watts for help with preparing the English manuscript. Fluorescence confocal microscopy
472 observations were done at the ICCF (Imagerie Confocale de Clermont-Ferrand) Centre, France.
473 TEM and SEM observations were done at the Centre d'Imagerie Cellulaire Santé (Clermont-
474 Ferrand, France).

475

476 **REFERENCES**

- 477 **Agol, V. I. & Gmyl, A. P. (2010).** Viral security proteins: counteracting host defences. *Nat*
478 *Rev Microbiol* **8**, 867–878.
- 479
- 480 **Antona, D., Lévêque, N., Chomel, J. J., Dubrou, S., Lévy-Bruhl, D. & Lina, B. (2007).**
481 Surveillance of enteroviruses in France, 2000-2004. *Eur J Clin Microbiol Infect Dis* **26**, 403–
482 412.
- 483
- 484 **Bailly, J. L., Chambon, M., Peigue-Lafeuille, H., Laveran, H., De Champs, C. & Beytout,**
485 **D. (1991).** Activity of glutaraldehyde at low concentrations (less than 2%) against poliovirus
486 and its relevance to gastrointestinal endoscope disinfection procedures. *Appl Environ*
487 *Microbiol* **57**, 1156–1160.
- 488
- 489 **Belov, G. A., Nair, V., Hansen, B. T., Hoyt, F. H., Fischer, E. R. & Ehrenfeld, E. (2012).**
490 Complex dynamic development of poliovirus membranous replication complexes. *J Virol* **86**,
491 302–312.
- 492
- 493 **Bergelson, J. M., Chan, M., Solomon, K. R., St John, N. F., Lin, H. & Finberg, R. W.**
494 **(1995).** Decay-accelerating factor (CD55), a glycosylphosphatidylinositol-anchored
495 complement regulatory protein, is a receptor for several echoviruses. *PNAS (USA)* **91**, 6245–
496 6248.
- 497
- 498 **Bergelson, J. M., St John, N., Kawaguchi, S., Chan, M., Stubdal, H., Modlin, J. &**
499 **Finberg, R. W. (1993).** Infection by Echoviruses 1 and 8 Depends on the cx2 Subunit of
500 Human VLA-2. *J Virol* **67**, 6847–6852.
- 501
- 502 **Bozym, R. A., Morosky, S. A., Kim, K. S., Cherry, S. & Coyne, C. B. (2010).** Release of
503 intracellular calcium stores facilitates coxsackievirus entry into polarized endothelial cells.
504 *PLoS Pathog* **6**, e1001135.
- 505
- 506 **Conaldi, P. G., Serra, C., Mossa, A., Falcone, V., Basolo, F., Camussi, G., Dolei, A. &**
507 **Toniolo, A. (1997).** Persistent infection of human vascular endothelial cells by group B
508 coxsackieviruses. *J Infect Dis* **175**, 693-696.
- 509
- 510 **Chen, C. S., Yao, Y. C., Lin, S. C., Lee, Y. P., Wang, Y. F., Wang, J. R., Liu, C. C., Lei,**
511 **H. Y. & Yu, C. K. (2007).** Retrograde axonal transport: a major transmission route of
512 enterovirus 71 in mice. *J Virol* **81**, 8996–9003.
- 513
- 514 **Cheng, H. Y., Huang, Y. C., Yen, T. Y., Hsia, S. H., Hsieh, Y. C., Li, C. C., Chang, L. Y.,**
515 **& Huang, L. M. (2014).** The correlation between the presence of viremia and clinical severity
516 in patients with enterovirus 71 infection: a multi-center cohort study. *BMC Infect Dis* **14**, 417.
- 517
- 518 **Coyne, C. B., Kim, K. S. & Bergelson, J. M. (2007).** Poliovirus entry into human brain
519 microvascular cells requires receptor-induced activation of SHP-2. *EMBO J* **26**, 4016–4028.
- 520
- 521 **Eberle, K. E., Nguyen, V. T. & Freistadt, M. S. (1995).** Low levels of poliovirus replication
522 in primary human monocytes: possible interactions with lymphocytes. *Arch Virol* **140**, 2135-
523 2150.
- 524

525 **Engelhardt, B. & Coisne, C. (2011).** Fluids and barriers of the CNS establish immune
526 privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS
527 castle. *Fluids and Barriers of the CNS* **8**, 4.
528

529 **Gromeier, M., & Wimmer E. (1998).** Mechanism of injury-provoked poliomyelitis. *J Virol*
530 **72**, 5056–5060.
531

532 **Haddad, A., Nokhbeh, M. R., Alexander, D. A., Dawe, S. J., Gris , C., Gulzar, N. &**
533 **Dimock, K. (2004).** Binding to decay-accelerating factor is not required for infection of human
534 leukocyte cell lines by enterovirus 70. *J Virol* **78**, 2674-2681.
535

536 **Khetsuriani, N., Lamonte-Fowlkes, A., Oberste, S. & Pallansch, M. A. (2006).** Centers for
537 Disease Control and Prevention. Enterovirus surveillance-United States, 1970-2005. *MMWR*
538 *Surveill Summ* **55**, 1–20.
539

540 **Kim, S., Kim, H. Y., Lee, S., Kim, S. W., Sohn, S., Kim, K. & Cho, H. (2007).** Hepatitis B
541 virus x protein induces perinuclear mitochondrial clustering in microtubule- and Dynein-
542 dependent manners. *J Virol* **81**, 1714–1726.
543

544 **Khong, W. X., Yan, B., Yeo, H., Tan, E. L., Ng, J. K. W., Chow, V. T. & Alonso, S. (2012).**
545 A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing
546 neurological manifestations in a novel mouse model of EV71 infection. *J Virol* **86**, 2121–2131.
547

548 **Lancaster, K. Z., & Pfeiffer, J. K. (2010).** Limited trafficking of a neurotropic virus through
549 inefficient retrograde axonal transport and the type I interferon response. *PLoS Pathog* **6**,
550 e1000791.
551

552 **Liang, C. C., Sun, M. J., Lei, H. Y., Chen, S. H., Yu, C. K., Liu, C. C., Wang, J. R., & Yeh**
553 **TM. (2004).** Human endothelial cell activation and apoptosis induced by enterovirus 71
554 infection. *J Med Virol* **74**, 597-603.
555

556 **Limpens, R. W., van der Schaar, H. M., Kumar, D., Koster, A. J., Snijder, E. J., van**
557 **Kuppeveld, F. J. & B rcena, M. (2011).** The transformation of enterovirus replication
558 structures: a three-dimensional study of single- and double-membrane compartments. *MBio* **2**,
559 00166–11.
560

561 **Merilahti, P., Koskinen, S., Heikkil , O., Karelehto, E. & Susi, P. (2012).** Endocytosis of
562 integrin-binding human picornaviruses. *Adv Virol* **2012**, 547530.
563

564 **Nishikawa, M., Matsubara, T., Yoshitomi, T., Ichiyama, T., Hayashi, T. & Furukawa, S.**
565 **(2000).** Abnormalities of brain perfusion in echovirus type 30 meningitis. *J Neurol Sci* **179**,
566 122 – 126.
567

568 **Ohka, S., Nihei, C., Yamazaki, M. & Nomoto, A. (2012).** Poliovirus trafficking toward
569 central nervous system via human poliovirus receptor-dependent and –independent pathway.
570 *Frontiers Microbiol* **2012**, 00147.
571

572 **Rotbart, H. A. (1995).** Meningitis and encephalitis. In *Human enterovirus infections*, pp 271-
573 289. Edited by H. A. Rotbart. Washington D. C., ASM Press.
574

575 **Ren, R. & Racaniello, V. R. (1992).** Poliovirus spreads from muscle to the central nervous
576 system by neural pathways. *J Infect Dis* **166**, 747–752.
577

578 **Rojo, G., Chamorro, M., Salas, M. L., Viñuela, E., Cuezva, J. M. & Salas, J. (1998).**
579 Migration of mitochondria to viral assembly sites in African swine fever virus-infected cells.
580 *J Virol* **72**, 7583–7588.
581

582 **Sabin, A. B. (1956).** Pathogenesis of poliomyelitis; reappraisal in the light of new data. *Science*
583 **123**, 1151-1157.
584

585 **Saijets, S., Ylipaasto, P., Vaarala, O., Hovi, T., & Roivainen, M. (2003).** Enterovirus
586 infection and activation of human umbilical vein endothelial cells. *J Med Virol* **70**, 430-439.
587

588 **Spindler, K. R. & Hsu, T. H. (2012).** Viral disruption of the blood-brain barrier. *Trends*
589 *Microbiol* **20**, 282–290.
590

591 **Stamatovic, S. M., Sladojevic, N., Keep, R. F. & Andjelkovic, A. V. (2012).** Relocalization
592 of junctional adhesion molecule A during inflammatory stimulation of brain endothelial cells.
593 *Mol Cell Biol* **32**, 3414–3427.
594

595 **Tabor-Godwin, J. M., Ruller, C. M., Bagalso, N., An, N., Pagarigan, R. R., Harkins, S.,**
596 **Gilbert, P. E., Kiosses, W. B., Gude, N. A., Cornell, C. T. & other authors (2010).** A novel
597 population of myeloid cells responding to coxsackievirus infection assists in the dissemination
598 of virus within the neonatal CNS. *J Neurosci* **30**, 8676–8691.
599

600 **Verma, S., Kumar, M., Gurjav, U., Lum, S., Nerurkar, V. R. (2010).** Reversal of West Nile
601 virus-induced blood-brain barrier disruption and tight junction proteins degradation by matrix
602 metalloproteinases inhibitor. *Virology* **397**,130-138.
603

604 **Verma, S., Lo, Y., Chapagain, M., Lum, S., Kumar, M., Gurjav, U., Luo, H., Nakatsuka,**
605 **A. & Nerurkar, V. R. (2009).** West Nile virus infection modulates human brain microvascular
606 endothelial cells tight junction proteins and cell adhesion molecules: Transmigration across the
607 in vitro blood-brain barrier. *Virology* **385**, 425-433.
608

609 **Volle, R., Bailly, J. L., Mirand, A., Pereira, B., Marque-Juillet, S., Chambon, M.,**
610 **Regagnon, C., Brebion, A., Henquell, C. & other authors (2014).** Variations in
611 cerebrospinal fluid viral loads among enterovirus genotypes in patients hospitalized with
612 laboratory-confirmed meningitis due to enterovirus. *J Infect Dis* **210**, 576–584.
613

614 **Volle, R., Nourrisson C., Mirand, A., Regagnon, C., Chambon, M., Henquell, C., Bailly,**
615 **J. L., Peigue-Lafeuille, H. & Archimbaud, C. (2012).** Quantitative real-time RT-PCR assay
616 for research studies on enterovirus infections in the central nervous system. *J Virol Methods*
617 **185**, 142–148.
618

619 **Vuorinen, T., Vainionpää, R., Vanharanta, R. & Hyypiä, T. (1996).** Susceptibility of
620 human bone marrow cells and hematopoietic cell lines to coxsackievirus B3 infection. *J Virol*
621 **70**, 9018-9023.
622

623 **Wahid, R., Cannon, M. J. & Chow, M. (2005a).** Virus-specific CD4+ and CD8+ cytotoxic
624 T-cell responses and long-term T-cell memory in individuals vaccinated against polio. *J Virol*
625 **79**, 5988-5995.

626

627 **Wahid, R., Cannon, M. J. & Chow, M. (2005b).** Dendritic cells and macrophages are
628 productively infected by poliovirus. *J Virol* **79**, 401-9.

629

630 **Weksler, B., Romero, I. A. & Couraud, P. O. (2013).** The hCMEC/D3 cell line as a model
631 of the human blood brain barrier. *Fluids Barriers CNS* **10**, 16.

632

633 **Weksler, B., Subileau, E. A., Perrière, N., Charneau, P., Holloway, K., Leveque, M.,**
634 **Tricoire-Leignel, H., Nicotra, A., Bourdoulous, S. & other authors (2005).** Blood-brain
635 barrier-specific properties of a human adult brain endothelial cell line. *FASEB J* **19**, 1872–
636 1874.

637

638 **Yang, W. X., Terasaki, T., Shiroki, K., Ohka, S., Aoki, J., Tanabe, S., Nomura, T.,**
639 **Terada, E., Sugiyama, Y. & Nomoto, A. (1997).** Efficient delivery of circulating poliovirus
640 to the central nervous system independently of poliovirus receptor. *Virology* **229**, 421–428.

641

642 **Yen, M. H., Tsao, K. C., Huang, Y. C., Huang, C. G., Huang, Y. L., Lin, R., Chang, M.**
643 **L., Huang, C. C., Yan, D. C., & Lin, T. Y. (2007).** Viral load in blood is correlated with
644 disease severity of neonatal coxsackievirus B3 infection: early diagnosis and predicting disease
645 severity is possible in severe neonatal enterovirus infection. *Clin Infect Dis* **44**, e78–81.

646

647 **Ylipaasto, P., Eskelinen, M., Salmela, K., Hovi, T. & Roivainen, M. (2010).** Vitronectin
648 receptors, α v integrins, are recognized by several non-RGD-containing echoviruses in a
649 continuous laboratory cell line and also in primary human Langerhans' islets and endothelial
650 cells. *J Gen Virol* **91**, 155–165.

651

652 **Zanone, M. M., Favaro, E., Conaldi, P. G., Greening, J., Bottelli, A., Perin, P. C., Klein,**
653 **N. J., Peakman, M. & Camussi, G. (2003).** Persistent infection of human microvascular
654 endothelial cells by coxsackie B viruses induces increased expression of adhesion molecules.
655 *J Immunol* **171**, 438–446.

656

657 **Zhang, Y., Cui, W., Liu, L., Wang, J., Zhao, H., Liao, Y., Na, R., Dong, C., Wang, L. &**
658 **other authors (2011).** Pathogenesis study of enterovirus 71 infection in rhesus monkeys. *Lab*
659 *Invest* **91**, 1337–1350.

Figure 1




Figure 2

		Dimension 1			d=1
Dimension 2		E-12 cf1157-91	E-6 cf2660-01	E-30 cf282-97	E-6 cf158061-11 E-30 cf220062-05 EV-A71 cf166105-10 E-13 cf1925-01
				E-13 cf1274-00	E-30 cf2575-00 E-16 cf187056-09 E-25 cf199022-07 CV-B3 NANCY E-18 tr115015-05
					E-1 FAROUK

Figure 3






Figure 4


Mock




E-6 / CF2660-01



E-12 / CF1157-91



E-30 / CF2575-00



EV-A71 / CF166105-10




Figure 5




Figure 6




Figure 7




Figure 8




Figure S1




Fig. S1. Schematic representation of the strategy used for testing the susceptibility of hCMEC/D3 cells to a large array of enterovirus types. Virus production per cell was assessed in hCMEC/D3 cells cultured in 96-wells plates. A total of 88 different EV strains were tested in two independent replicates. The whole cell monolayers and supernatants were harvested at 24 h p.i. The amount of viral genomes and infectious particles were quantified by RT-qPCR and viral titration respectively. Cell mortality was analysed during virus infection of hCMEC/D3 cells cultured in 12-well plates; 15 EV strains were compared in 4 independent replicates. Cells were collected, stained for apoptosis and necrosis testing, and counted by flow cytometry at 24 h p.i. Infection efficiency was assessed in cells cultured in 8-well labtek® culture slides. The hCMEC/D3 cells were inoculated with 50 different EV strains. At 6 h p.i., before massive release of progeny viruses, cells were fixed, immunostained for viral protein VP1 and nuclear DNA, and observed at low magnification (10X) with an epifluorescence microscope. The pictures were then analysed to determine the proportion of infected cells.

Figure S2




Fig. S2. Correlation circle of the principal component analysis showing the variables linked with horizontal and vertical axis.

Figure S3




Fig. S3. In vitro model of brain endothelial barrier of polarized hCMEC/D3.

Schematic representation of the model of a blood-brain endothelial barrier obtained by culture of hCMEC/D3 cells at the surface of a permeable membrane (0.4 μm pore; coated with rat collagen-I) included within the upper chamber of a Transwell® device (a). Lucifer yellow (LY) paracellular permeability was measured for 11 days after seeding cells in different independent experiments representative of triplicate cultures (b). Transverse observations by transmission electron microscopy of a polarized hCMEC/D3 cell monolayer (culture of 7 days), scale bar 2 μm (c). Intercellular junction, scale bar 200 nm (d), with a high magnification showing an electron-dense tight junction, with the measurements of intercellular spaces, scale bar 100 nm (e).

Figure S4




Fig. S4. Ultrastructural features of mock infected cells of an *in vitro* model of blood-brain endothelial barrier.

Low-magnification transmission electron micrograph of 7-day hCMEC/D3 monolayers (a and b). Confocal observation of mitochondria network (red) in hCMEC/D3 cells (c), High magnification transmission electron micrograph of 7-days cultures hCMEC/D3 monolayer. A central nucleus is surrounded by plenty of mitochondria near the rough endoplasmic reticulum (d). Bars represent, 10 μm (a – c); 5 μm (d). N, nucleus; M, mitochondria; ER, endoplasmic reticulum.

General features of Enterovirus strains			Clinical features		
Species	Serotypes	Strains	Isolation source	Clinical manifestations	
A	CV-A2	CF192073-11	Throat	Encephalitis	
		CF197013-11	Feces	Guillain Barre	
	CV-A4	CF308011-10	Throat	Hand-Foot and Mouth disease	
		CF063006-11	Feces	Fever	
	CV-A5	CF193056-11	Feces	Acute meningitis	
	CV-A6	CF218013-10	Throat	Hand-Foot and Mouth disease	
		CF605-00	Feces	Septic shock	
	EV-A71	CF166105-10	Throat	Hand-Foot and Mouth disease	
		CF160019-10	Throat	Hand-Foot and Mouth disease	
	CV-A9	CF027040-07	Throat	Acute meningitis	
	CV-B1	CF741-93	Feces		
		CF217010-08	Feces		
	CV-B2	CF314051-04	Throat		
		CF186019-07	Throat	Acute meningitis	
			NANCY	Stools	Minor febrile illness
	CV-B3	CF183076-08	Throat	Throat	Acute meningitis
		CF193061-05	Throat	Throat	Acute meningitis
CV-B4	CF169091-07	Throat	Throat	Acute meningitis	
	CF516-00	CSF	CSF	Headache; Fever; Vomiting	
CV-B5	CF186106-05	Throat	Throat	Acute meningitis	
	CF202076-06	Throat	Throat	Acute meningitis	
CV-B6	SCHMITT	Stools	Stools	None	
	CF132-87				
E1	FAROUK	Stools	Stools	None	
E2	CORNELIS	Stools	Stools	Acute meningitis	
	CF307001-05	Feces	Feces	Acute meningitis suspected	
E3	MORRISSEY	Stools	Stools	Acute meningitis	
	CF180108-05	Throat	Throat		
		DUTOIT			
E4	CF248076-05	Feces	Feces	Acute meningitis	
	CF101013-08	Feces	Feces	Acute meningitis	
E5	NOYCE	Stools	Stools	Acute meningitis	
	CF990-00	CSF	CSF	Acute meningitis	
	CF2660-01	CSF	CSF	Acute meningitis	
	CF1057-00	CSF	CSF	Acute meningitis	
	CF328087-03	Throat	Throat	Acute meningitis	
	CF671-00	CSF	CSF	Acute meningitis	
	CF1634-01	CSF	CSF	Acute meningitis	
E6	CF1679-02	CSF	CSF	Acute meningitis	
	CF158061-11	Throat	Throat		
	CF185010-11	Throat	Throat	Acute meningitis	
	WALLACE	Stools	Stools	None	
	CF185103-05	Throat	Throat	Acute meningitis	
E7	CF293042-06	Throat	Throat	Acute meningitis	
	CF22-80				
E9	CF1462-00	CSF	CSF	Acute meningitis	
	CF228046-07	Throat	Throat	Acute meningitis suspected	
B	E11	CF1157-91			
		DELCARMEN	Stools	Stools	None
	E12	CF1083-91			
		CF1274-00	CSF	CSF	Acute meningitis
		CF1925-01	CSF	CSF	Acute meningitis
		CF1393-00	CSF	CSF	Acute meningitis
		CF1901-00	Throat	Throat	Acute meningitis
	E13	CF282003-06	Throat	Throat	Acute meningitis
		TOW	Stools	Stools	Acute meningitis
	E14	CF225059-08	Feces	Feces	
		CHARLESTON	Stools	Stools	None
	E15	CF187056-09	Feces	Feces	Acute meningitis
		CF596-78			
E16	METCALF	Stools	Stools	Diarrhea	
	CF279084-05	Throat	Throat	Acute meningitis	
E17	TR115015-05				
	BURKE	Stools	Stools	Diarrhea	
E18	JV1	Stools	Stools	Fever	
	FARINA	Stools	Stools	Acute meningitis	
E19	DECAMP	Stools	Stools	Diarrhea	
	JV4	Stools	Stools	Diarrhea	
E20	CF205083-06	Throat	Throat	Acute meningitis	
	CF199022-07	Feces	Feces	Acute meningitis	
E21	CORONEL	Stools	Stools	None	
	BACON	Stools	Stools	None	
E22	JV10	Stools	Stools	None	
	BASTIANNI	CSF	CSF	Acute meningitis	
E23	CF1260-78				
	CF1074-78				
	CF282-97	Feces	Feces	Acute meningitis	
	CF552-00	Feces	Feces	Acute meningitis	
	CF2575-00	CSF	CSF	Acute meningitis	
	CF220062-05	Throat	Throat	Acute meningitis	
	CF307026-07	Throat	Throat	Acute meningitis	
E24	CF284052-07	Throat	Throat	Acute meningitis	
	CALDWELL	Stools	Stools	Acute meningitis	
E25	CF235069-05	Throat	Throat	Acute meningitis	
	TOLUCA1	Rectal swab	Rectal swab	None	
E26	EV-B69				
	EV-B77				
C	CV-A21	CF1069-91			
	EV-D70	CF670-71			